Neurotrope Inc.

Neurotrope Inc., founded in 2012, is a promising clinical-stage biotech company headquartered in the United States. With the slogan, "Developing a new approach to combating Alzheimer's disease and other neurodegenerative diseases," the company is focused on discovering restorative therapeutics aimed at major neurodegenerative and developmental disorders.

Neurotrope's strategy centers on leveraging Bryostatin-1 and its analogues to develop targeted treatments for conditions such as Alzheimer's Disease, Fragile X Syndrome, and Niemann-Pick Type C. The company's dedication to novel drug therapies has driven it to build a robust pipeline, positioning it as a potential leader in its field.

The most recent funding event for Neurotrope was a $21.90M Series A investment in September 2013. While detailed information about the investors was not provided, this investment underscores a strong early endorsement of their innovative approach. Positioned within the Biotechnology and Health Care industries, Neurotrope warrants close attention from investors seeking pioneering solutions in healthcare.